Core Insights - CROSSJECT reported its financial results for the first half of 2025, highlighting progress in regulatory activities and financial performance [3][4][9]. Financial Performance - The company recorded revenues of €8,038,000 for H1 2025, an increase from €5,766,000 in H1 2024 [13]. - R&D reimbursements from BARDA rose significantly to €6,584,000 in H1 2025, compared to €3,064,000 in H1 2024, reflecting increased R&D activities [13][19]. - The operating loss improved to €5,139,000 in H1 2025 from €6,719,000 in H1 2024, indicating better cost management [14]. - The net loss for the period was €4,868,000, down from €6,402,000 in the same period last year [14]. Regulatory and Development Activities - CROSSJECT continued its regulatory efforts with BARDA to obtain Emergency Use Authorization (EUA) for ZEPIZURE® in the U.S. [4][9]. - The company produced validation batches in collaboration with its CDMO partner EUROFINS, which are part of the EUA dossier [5]. - In September 2025, CROSSJECT secured an €11.3 million extension of R&D funding from the U.S. government [5]. Production and Innovation - The company finalized the development of the ZENEO® Nest module to enhance aseptic filling operations, preparing for increased production volumes [7]. - CROSSJECT maintained a cash position of €6.3 million as of June 30, 2025, down from €7.0 million at the end of 2024, reflecting effective resource management [9]. Strategic Collaborations - The company strengthened its marketing strategy for ZEPIZURE® by collaborating with opinion leaders in epilepsy and emergency medicine [8]. - In preparation for potential FDA inspections, BARDA conducted mock audits during the summer [10].